Abstract
Monoclonal antibodies against the calcitonin gene-related peptide (CGRP) receptor (erenumab) or against CGRP (eptinezumab, fremanezumab, galcanezumab) are new substances for the preventive treatment of migraine. They represent an extension of the therapeutic options which already exist in migraine prevention. In registration studies, the efficacy and good tolerability of these specific substances have been demonstrated in patients with episodic and chronic migraine. The following treatment recommendation presents a summary of the pivotal studies. Recommendations are given for the targeted selection of patients as well as for the evaluation of therapeutic success and the duration of treatment. Finally, possible restrictions in the use of this new substance group are discussed.
Bidragets oversatte titel | Guidelines for diagnosis and therapy in neurology: Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor. Supplement to the guideline 030/057 for the therapy of migraine attacks and prevention of migraine |
---|---|
Originalsprog | Tysk |
Tidsskrift | Arzneimitteltherapie |
Vol/bind | 38 |
Udgave nummer | 3 |
Sider (fra-til) | 69-92 |
Antal sider | 24 |
ISSN | 0723-6913 |
Status | Udgivet - 1 jan. 2020 |